Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 3 | 2018 | 293 | 1.430 |
Why?
|
| Burkitt Lymphoma | 3 | 2024 | 144 | 1.020 |
Why?
|
| Methotrexate | 2 | 2025 | 341 | 0.990 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 236 | 0.990 |
Why?
|
| Capacity Building | 1 | 2025 | 24 | 0.960 |
Why?
|
| Hematologic Diseases | 1 | 2025 | 76 | 0.900 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 141 | 0.860 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 181 | 0.860 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1237 | 0.860 |
Why?
|
| Malawi | 11 | 2025 | 396 | 0.810 |
Why?
|
| Mucositis | 1 | 2022 | 18 | 0.810 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 164 | 0.720 |
Why?
|
| Sarcoma, Kaposi | 4 | 2023 | 120 | 0.700 |
Why?
|
| Malnutrition | 1 | 2022 | 204 | 0.640 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 299 | 0.620 |
Why?
|
| Neoplasms | 5 | 2025 | 2788 | 0.580 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 298 | 0.540 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 160 | 0.530 |
Why?
|
| Child | 21 | 2025 | 24453 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2017 | 351 | 0.480 |
Why?
|
| Africa South of the Sahara | 3 | 2025 | 115 | 0.460 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 49 | 0.380 |
Why?
|
| Vincristine | 2 | 2020 | 195 | 0.310 |
Why?
|
| HIV Infections | 4 | 2023 | 1896 | 0.280 |
Why?
|
| Child, Preschool | 8 | 2025 | 14050 | 0.280 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 421 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2025 | 16299 | 0.270 |
Why?
|
| Adolescent | 10 | 2025 | 19329 | 0.250 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 21 | 0.240 |
Why?
|
| Humans | 22 | 2025 | 124793 | 0.240 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5153 | 0.240 |
Why?
|
| Legal Guardians | 1 | 2024 | 12 | 0.240 |
Why?
|
| Male | 14 | 2025 | 61283 | 0.220 |
Why?
|
| Drug Monitoring | 1 | 2025 | 170 | 0.220 |
Why?
|
| Female | 14 | 2025 | 66553 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Malaria, Falciparum | 1 | 2022 | 48 | 0.200 |
Why?
|
| Quality of Life | 2 | 2022 | 1948 | 0.200 |
Why?
|
| Malaria | 1 | 2022 | 83 | 0.190 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 17 | 0.190 |
Why?
|
| Wilms Tumor | 1 | 2023 | 113 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 37 | 0.190 |
Why?
|
| Creatinine | 1 | 2022 | 390 | 0.180 |
Why?
|
| Terminal Care | 1 | 2022 | 112 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 422 | 0.170 |
Why?
|
| Nutritional Status | 1 | 2022 | 313 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 224 | 0.170 |
Why?
|
| Anemia | 1 | 2023 | 340 | 0.160 |
Why?
|
| Vinblastine | 1 | 2018 | 48 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 431 | 0.150 |
Why?
|
| Prednisolone | 1 | 2018 | 74 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 339 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 848 | 0.150 |
Why?
|
| Etoposide | 1 | 2018 | 117 | 0.150 |
Why?
|
| Lymphoma | 1 | 2021 | 323 | 0.150 |
Why?
|
| Dacarbazine | 1 | 2018 | 86 | 0.150 |
Why?
|
| Bleomycin | 1 | 2018 | 150 | 0.150 |
Why?
|
| Podophyllotoxin | 1 | 2017 | 7 | 0.140 |
Why?
|
| Carmustine | 1 | 2017 | 26 | 0.140 |
Why?
|
| Autografts | 1 | 2017 | 26 | 0.140 |
Why?
|
| Melphalan | 1 | 2017 | 49 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 98 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2018 | 297 | 0.140 |
Why?
|
| Infant | 5 | 2025 | 12482 | 0.140 |
Why?
|
| Prognosis | 3 | 2025 | 4607 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2025 | 6137 | 0.130 |
Why?
|
| Pediatrics | 1 | 2025 | 1155 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 868 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.120 |
Why?
|
| Cytokines | 1 | 2019 | 1290 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1105 | 0.100 |
Why?
|
| Survival Rate | 1 | 2017 | 2035 | 0.100 |
Why?
|
| Adult | 4 | 2024 | 29471 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3448 | 0.060 |
Why?
|
| Risk Factors | 1 | 2018 | 10272 | 0.060 |
Why?
|
| Tanzania | 1 | 2023 | 68 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 177 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2024 | 548 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2021 | 173 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 191 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 611 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 213 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 132 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8182 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 170 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 654 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 398 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 607 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1247 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 459 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1228 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 673 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 429 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 777 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2019 | 421 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 2451 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1004 | 0.030 |
Why?
|
| United States | 1 | 2023 | 10885 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8987 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 26716 | 0.010 |
Why?
|